Table 1 Patient and treatment characteristics at baseline
From: Concurrent whole brain radiotherapy and bortezomib for brain metastasis
No. of patients | |
|---|---|
Screened | 27 |
On-study | 24 |
Gender, n (%) | |
Female | 14 (58) |
Male | 10 (42) |
Median age, years (range) | 58 (41–76) |
Underlying malignancy, n (%) | |
Melanoma | 20 (83) |
Non-small cell lung cancer | 2 (8) |
Renal cell carcinoma | 1 (4) |
Breast | 1 (4) |
No. previous systemic therapies | |
Median (range) | 0 (0–9) |
No. of brain metastases | |
Median (range) | 5 (1- ≥ 10) |
Neurologic symptoms at baseline, n (%) | |
Yes | 12 (50) |
No | 12 (50) |
Dexamethasone use, n (%) | |
Yes | 17 (71) |
No | 7 (29) |
Craniotomy*, n (%) | |
Yes | 2 (8) |
No | 22 (92) |
Anti-epileptic medication use, n (%) | |
Yes | 2 (8) |
No | 22 (92) |
Bortezomib dose (mg/m2/dose), n (%) | |
0.9 | 5 (21) |
1.1 | 4 (17) |
1.3 | 4 (17) |
1.5 | 2 (8) |
1.7 | 9 (37) |
Radiation dose, n (%) | |
30 Gy (3 Gy fractions) | 19 (79) |
37.5 Gy (2.5 Gy fractions) | 5 (21) |